- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02879669
A Randomised Phase II Open-label Study With a Phase Ib Safety lead-in Cohort of ONCOS-102, an Immune-priming GM-CSF Coding Oncolytic Adenovirus, and Pemetrexed/Cisplatin in Patients With Unresectable Malignant Pleural Mesothelioma
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Dijon, France
- Centre Georges-Francois Leclerc
-
Rennes, France
- CHU de Rennes - Pontchaillou
-
-
-
-
-
Barcelona, Spain
- Hospital Universitario Quirón
-
Barcelona, Spain
- Vall d'Hebron Univerity Hospital
-
Girona, Spain
- Hospital Universitari de Girona Doctor Josep Trueta - Institut Català d'Oncologia
-
Madrid, Spain
- Hospital 12 de Octubre
-
Madrid, Spain
- Hospital Universitario HM Sanchinarro
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Written informed consent.
- Male or female, ≥18 years of age.
Histologically confirmed unresectable (advanced) malignant pleural mesothelioma in patients who are not candidates for curative surgery and for whom therapy with pemetrexed in combination with cisplatin or carboplatin is considered appropriate. This include:
- patients who are naïve to chemotherapy,
- and those who have already received pemetrexed in combination with cisplatin or carboplatin to which their tumour initially responded, but they have relapsed after at least 6 months.
The patient may be evaluated by a multidisciplinary consultation (according to hospital procedure), however the final decision about the inclusion of a patient is made by the principal investigator.
- Measurable disease according to Response Evaluation in Solid Tumour (RECIST 1.1).
- Tumour must be accessible to intratumoural (i.t.) injections and to tumour core needle biopsy or thoracoscopy for tissue sampling and immunohistochemistry analysis.
- The patients must be eligible to receive the study specific chemotherapies, including cyclophosphamide, according to the SPCs and local practice.
- Eastern Cooperative Oncology Group (ECOG)/World Health Organization (WHO) performance score 0 to 1.
- Acceptable liver, renal, and haematological functions.
- All women of childbearing potential must have a negative urine or serum pregnancy test at screening and all patients must agree to use barrier contraception (i.e. condom) during study treatment and for 2 months after the last virus treatment, 6 months after the last dose of pemetrexed/cisplatin/carboplatin and 12 months after the dose of cyclophosphamide.
Exclusion Criteria:
- Receipt of oncolytic virus treatment, or vaccination with a vaccine containing live virus within 4 weeks before Day 1.
- Use of significant immunosuppressive medication, including high dose corticosteroid (defined as the equivalent of >10 mg/day prednisone) within 4 weeks before Day 1.
- Patients who participated in a study with an investigational drug or device within 4 weeks prior to Day 1.
- Active bacterial, viral, or fungal infections, requiring systemic therapy.
- Severe arrhythmia, heart failure, previous cardiac infarction, or acute inflammatory heart disease.
- Concomitant disease or condition that could interfere with the conduct of the study, or that would, in the opinion of the Investigator, pose an unacceptable risk to the patient, if included in this study.
- Known infection with HIV, hepatitis B, or hepatitis C.
- Known brain metastases.
- History of organ transplant.
- Females who are pregnant or breast feeding.
- Unwillingness or inability to comply with the study protocol for any reason.
- Patients with pre-existing hearing loss or neuropathy that may worsen due to potential neurotoxicity from cisplatin.
- Patients with a history of hypersensitivity to cisplatin or carboplatin or pemetrexed or cyclophosphamide (or any of its metabolites).
- Patients who are taking phenytoin for prophylactic use.
- History of malignant tumour, unless the patient has been without evidence of disease for at least 3 years, or the tumour was a non-melanoma skin tumour, cervical carcinoma in situ, or prostatic carcinoma in situ.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ONCOS-102+cyclophosphamide+pemetrexed/cisplatin (carboplatin)
ONCOS-102 will be administered in a priming cycle (Cycle 1) comprising injections on Days 1, 4, 8 and 36, followed by two treatment cycles at intervals of 6 weeks (Cycle 2, Day 78 and Cycle 3, Day 120).
Pre-treatment with an i.v.
bolus of cyclophosphamide (CPO) will be given 1 to 3 days before the first administration of ONCOS-102 (Cycle 1, Day 1) and before administration of Cycle 2 of ONCOS-102 (Day 78).
Patients will also receive pemetrexed/cisplatin (carboplatin) in 21-day cycles starting on Day 22 and continuing as applicable during the study period of 6 cycles of pemetrexed/cisplatin (carboplatin) in combination with ONCOS-102.
|
|
Active Comparator: Pemetrexed/cisplatin (carboplatin)
Patients will be treated with pemetrexed/cisplatin (carboplatin) in 21-day cycles starting on Day 1, and continuing as applicable during the study period of 6 cycles of chemotherapy.
Patients will be monitored regularly for immunological assessment (PBMCs) including Month 9 and Month 12 (i.e., after the end of study visit), and will be followed up for survival every 3 months until end of life.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of patients with any (Serious and Non-Serious) Adverse Event measured to assess safety and tolerability
Time Frame: 6 months
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To determine and compare tumour-specific immunological activation in the peripheral blood in the experimental group and the control group. Number of patients in the respective arms with induction of Tumor specific CD8+ T Cells in PBMC
Time Frame: 6 months
|
6 months
|
To determine and compare immunological activation in tumour mass in the experimental group and the control Group. Number of patients in the respective arms with infiltration of CD8+ T Cells into tumours
Time Frame: 6 months
|
6 months
|
To determine and compare overall response rate in the experimental group and the control group by number of patients with PD, SD, PR and CR in the respective arms
Time Frame: 6 months
|
6 months
|
To determine and compare progression-free survival (PFS) in the experimental group and the control group by median time to progression in the respective arms
Time Frame: 6 months
|
6 months
|
To determine and compare overall survival (OS) in the experimental group and the control group
Time Frame: Until death
|
Until death
|
To analyse immunological activation by comparing patients with and without presence of tumour antigen recognizing CD8+ T cells
Time Frame: 6 months
|
6 months
|
To analyse clinical outcome by time to event endpoints (OS and PFS)
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Lung Neoplasms
- Adenoma
- Neoplasms, Mesothelial
- Pleural Neoplasms
- Mesothelioma
- Mesothelioma, Malignant
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Folic Acid Antagonists
- Cyclophosphamide
- Carboplatin
- Cisplatin
- Pemetrexed
Other Study ID Numbers
- ONCOS C719
- 2015-005143-13 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on To Determine Safety, Tolerability and Efficacy of ONCOS-102 in Combination With Chemotherapy
-
Shanghai General Hospital, Shanghai Jiao Tong University...Not yet recruitingTo Evaluate the Safety and Tolerability of Intravitreal Injection of LX109 in Patients With nAMD
-
Alex Ekwueme Federal University Teaching HospitalCompletedTo Determine Efficacy of Tranexamic Acid in Reducing Blood Loss During MyomectomyNigeria
-
Lee's Pharmaceutical LimitedFidia Farmaceutici s.p.a.CompletedThe Primary Objective of This Study Was to Assess the Efficacy and Safety of Hyaluronic Acid Vaginal Gel in Treating Vaginal Dryness
-
Synergy Health Concepts, Inc.UnknownTo Determine the Safety and Validity of Venous Angioplasty and | Valvuloplasty in the Treatment of CCSVI. In Addition, it Will | Allow Researchers to Sub-classify Valve Morphology in Relation | to Treatment Success. This Will be Evidenced by Venous Patency | Forty-eight Hours by Doppler... and other conditionsUnited States
-
Shanghai Children's Medical CenterNot yet recruitingTo Analyze and Compare the Efficacy and Safety of Ondansetron and Tablet for the Prevention of Moderate and Hypoemetic Chemotherapy
-
Chittagong Medical CollegeCompletedTo See the Safety and Efficacy of the Topical Latanoprost Compared With Topical Brimonidine in the Treatment of the Primary Open Angle Glaucoma PatientsBangladesh
-
Zhongnan HospitalNot yet recruitingEfficacy and Safety of Shen Hai Long Capsule for Mild to Moderate Asthenospermia in MenChina
-
Second Affiliated Hospital, School of Medicine,...Active, not recruitingEfficacy and Safety of Immunotherapy Combined With Neoadjuvant Chemotherapy in Patients With Locally Advanced HPV (-) HNSCCChina
-
Sohag UniversityCompletedDetermine the Efficacy and Safety of SWL in Renal Stones Larger Than 2 cm in Pediatric Age GroupEgypt
-
Johannes Gutenberg University MainzUnknownFocus of the Study is to Evaluate a New Developed Deep-learning Computer-aided Detection System in Combination With LCI for Colorectal Polyp DetectionGermany
Clinical Trials on Cyclophosphamide
-
Children's Hospital Los AngelesLucile Packard Children's HospitalTerminatedMetabolic Diseases | Stem Cell Transplantation | Chronic Granulomatous Disease | Bone Marrow Transplantation | Thalassemia | Wiskott-Aldrich Syndrome | Genetic Diseases | Peripheral Blood Stem Cell Transplantation | Pediatrics | Diamond-Blackfan Anemia | Allogeneic Transplantation | Combined Immune Deficiency | X-linked Lymphoproliferative Disease
-
Medical College of WisconsinNational Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaboratorsCompletedAnemia, AplasticUnited States
-
Columbia UniversityUnknownSevere Combined Immunodeficiency | Fanconi Anemia | Bone Marrow Failure | OsteopetrosisUnited States
-
National Cancer Institute, NaplesImmatics Biotechnologies GmbH; CureVac; European Commission -FP7-Health-2013-Innovation-1CompletedHepatocellular CarcinomaBelgium, Germany, Italy, Spain, United Kingdom
-
Eisai Inc.CompletedBreast Cancer | Ovarian Cancer | Prostate Cancer | Colon Cancer | Renal CancerUnited States
-
Mahidol UniversityTerminatedRenal Insufficiency | InfectionThailand
-
Centre Oscar LambretCompleted
-
Baylor Research InstituteCompletedMalignant Melanoma Stage IVUnited States
-
University of Turin, ItalyUnknown
-
Merck KGaA, Darmstadt, GermanyCompleted